Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy

BJU International

Volumn 110, Issue 8, 2012, Pages 1122-1128

  Pierorazio, Phillip M ^a   Ross, Ashley E ^a   Lin, Brian M ^a   Epstein, Jonathan I ^a   Han, Misop ^a   Walsh, Patrick C ^a   Partin, Alan W ^a   Pavlovich, Christian P ^a   Schaeffer, Edward M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Gleason sum; high risk; outcomes; prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER GRADING; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; SURVIVAL RATE;

ADULT; AGED; BIOPSY, NEEDLE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 84871904682     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.10986.x     Document Type: Article

References (26)

1. Grossfeld GD, Latini DM, Lubeck DP, Mehta SS, Carroll PR,. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol 2003; 169: 157-63
2. Pound CR, Partin AW, Epstein JI, Walsh PC,. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997; 24: 395-406
3. D'Amico AV, Whittington R, Malkowicz SB, et al,. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74
4. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC,. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555-65
5. Partin AW, Yoo J, Carter HB, et al,. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. Journal Urol 1993; 150: 110-4
6. Pierorazio PM, Guzzo TJ, Han M, et al,. Long-term survival after radical prostatectomy for men with high gleason sum in pathologic specimen. Urology 2010; 76: 715-21
7. Zelefsky MJ, Eastham JA, Cronin AM, et al,. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 2010; 28: 1508-13
8. Abdollah F, Sun M, Thuret R, et al,. A Competing-Risks Analysis of Survival After Alternative Treatment Modalities for Prostate Cancer Patients: 1988-2006. Eur Urol 2010; 59: 88-95
9. Loeb S, Schaeffer EM, Trock BJ, Epstein JI, Humphreys EB, Walsh PC,. What Are the Outcomes of Radical Prostatectomy for High-risk Prostate Cancer? Urology 2010; 76: 710-4
10. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR,. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 2003; 170: S21-7
11. Bastian PJ, Gonzalgo ML, Aronson WJ, et al,. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer 2006; 107: 1265-72
12. Chodak GW, Thisted RA, Gerber GS, et al,. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330: 242-8
13. Partin AW, Lee BR, Carmichael M, Walsh PC, Epstein JI,. Radical prostatectomy for high grade disease: a reevaluation 1994. J Urol 1994; 151: 1583-6
14. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM,. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999; 281: 1395-400
15. May M, Siegsmund M, Hammermann F, Loy V, Gunia S,. Visual estimation of the tumor volume in prostate cancer: a useful means for predicting biochemical-free survival after radical prostatectomy? Prostate Cancer Prostatic Dis 2007; 10: 66-71
16. Wolters T, Roobol MJ, van Leeuwen PJ, et al,. Should pathologists routinely report prostate tumour volume? The prognostic value of tumour volume in prostate cancer. Eur Urol 2010; 57: 821-9
17. Kikuchi E, Scardino PT, Wheeler TM, Slawin KM, Ohori M,. Is tumor volume an independent prognostic factor in clinically localized prostate cancer? J Urol 2004; 172: 508-11
18. Vollmer RT,. Percentage of tumor in prostatectomy specimens: a study of American Veterans. Am J Clin Pathol 2009; 131: 86-91
19. Van der Kwast TH, Bolla M, Van Poppel H, et al,. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007; 25: 4178-86
20. Wiegel T, Bottke D, Steiner U, et al,. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009; 27: 2924-30
21. Loblaw DA, Virgo KS, Nam R, et al,. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25: 1596-605
22. Walsh PC,. Urological oncology: prostate cancer: editorial comment on: intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. J Urol 2009; 182: 2728
23. Matzinger O, Duclos F, van den Bergh A, et al,. Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991. Eur J Cancer 2009; 45: 2825-34
24. Nelson CJ, Lee JS, Gamboa MC, Roth AJ,. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer 2008; 113: 1097-106
25. Lu-Yao GL, Albertsen PC, Moore DF, et al,. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008; 300: 173-81
26. Trock BJ, Han M, Freedland SJ, et al,. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008; 299: 2760-9